Abbvie Inc (ABBV)

$206.11 -2.05 (-0.98%)
Market Cap 365.30B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 20.74
Forward PE 14.87
Profit Margin 6.91%
Debt to Equity Ratio -20.91
Volume 4,427,261
Avg Vol 7,001,798
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 72%
Beta 0.32
Analysts Strong Sell
Price Target $250.90

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 5 at 7:10 PM
$SLS While we Continue to See Near Miraculous survival in all pooled patients, BAT for control Arm Patients Recently Failed, 3 large Phase 3 Trials conducted by $ABBV - Miraculous Survival in this Phase 3 REGAL Trial for Second Remission Maintenance CR2 - VIALE-M Aza+VEN Phase 3 Trial FAILURE for First Remission Maintenance CR1 3 P3 Fails for BAT --- it is not complicated.
0 · Reply
SellasgpsCurativeBAT9
SellasgpsCurativeBAT9 May. 5 at 6:18 PM
$SLS 125 Million+ Cash on hand per last 10K filing. Gps will be CURATIVE in over 20+ WT1 cancer Types. GPS Ad Infinitum Dosing will generate over $50 Billion+ annually for Big Pharmaceutical Suitors. GPs has already proven effective in Mesothelioma and Platinum Resistant Ovarian Cancer settings, achieving better Phase 2 Combination trial Results with Keytruda $MRK - MOS of 18.4 months - than, Elahere $IMGN 16.4 Months, which earned FDA Approval and was bought by $ABBV for $10.1B - this is just 1 comp worth $10B. SLS009 has already shown 4 times better response in phase 2b than current SOC. Bidding war is coming $280 Per share. Don’t step over hundred dollar 💵 Bills to pick up Pennie’s. Hold with Conviction. ✌️🙏❤️‍🩹
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 5 at 5:00 PM
$ABVX $SLS From $5 and change to a High of $148 - from $270M to $14B in Market Value - all based on the Value of a Phase 3 Registrational Catalyst. - GPS Phase 3 Results Are Coming and we ARE IN THE 80th Event WINDOW - While we continue to see Miraculous all pooled survival in the REGAL Phase 3 Trial, among Control Patients on BAT and GPs Combined ... BAT / Aza+VEN Recently FAILED 3 Large Phase 3 Trials, conducted by $ABBV including Failing 2 AML Remission Maintenance Trials ... Aza+Ven is Effective at Getting Front Line patients into Remission, but its not Durable - as Dr. Yair Levy Dir. of Heme Research at Baylor Med Stated. It is not complicated - Gps is the only reason we are seeing the Extended Survival in the Regal P3. 25 Months Since the Last Patient Enrolled, we are likely to see the Final Analysis Top Line Results ANY DAY NOW. And Gps is worth every bit of $40B to Big Pharma the INSTANT we see the PR.
1 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker May. 5 at 1:23 PM
$KYTX our new CCO Mrs. Nadia Dac made her marks throughout the industry working at $LLY $JNJ $PFE $ABBV & Novartis Network is everything for scaling this baby with a proper GTM 💲💲💲
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 4 at 8:01 PM
$SLS $ABBV
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 4 at 7:53 PM
$SLS Look at the share price when the 72nd event was announced - what do you think will happen when we see the 80th? SLS Market Cap is now up over 1,000% Since the IDMC Unblinded Actual Phase 3 MOS and IR data from the INTERIM ANALYSIS at 60 Events DEC 2024. +1,000% For a Reason --- The unblinded data - Gave most HEME Industry Players $ABBV $PFE the sign Gps is Golden, now 6 months since the 72nd Event, and this far along - 25 months since enrollment completed, and median follow-up of 31 months (25-63) ALL Smart Investors must reconcile the fact the 80th event and instant share price launch could occur at any time. Now 31 months Follow-Up in a setting of "High Leukemic Risk" Dr. Kantarian Chair of MD Anderson's Leukemia Dept., REGAL Phase 3 Global Lead and Steering Committee Chair.
0 · Reply
Garibs
Garibs May. 4 at 3:29 PM
$BSX $ABBV calls on both
0 · Reply
DefenseMania
DefenseMania May. 3 at 6:45 PM
$COST $VZ $MO $ABBV https://finance.yahoo.com/markets/stocks/articles/dividend-investors-know-costco-183500369.html
0 · Reply
NRG8
NRG8 May. 3 at 12:25 PM
$JNJ $ABBV $BAC $PG $CVX .
0 · Reply
Oldpuck
Oldpuck May. 1 at 10:54 PM
$ABBV I thought ABBV had turned the corner, just like it was before earnings
1 · Reply
Latest News on ABBV
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

May 5, 2026, 8:05 AM EDT - 8 hours ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 3:05 PM EDT - 4 days ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

Big Pharma M&A set for mega year as patent expiries drive deal urgency

May 1, 2026, 10:03 AM EDT - 4 days ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 3:00 PM EDT - 5 days ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 30, 2026, 9:00 AM EDT - 5 days ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

AbbVie Thanks 'Excellent Start To 2026' To Immunology And Neuroscience Strength

Apr 29, 2026, 2:49 PM EDT - 6 days ago

AbbVie Thanks 'Excellent Start To 2026' To Immunology And Neuroscience Strength

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 6 days ago

AbbVie Earnings Call Transcript: Q1 2026

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 6 days ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:50 AM EDT - 6 days ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 6 days ago

AbbVie Reports First-Quarter 2026 Financial Results

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 8:00 AM EDT - 7 days ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 28, 2026, 7:00 AM EDT - 7 days ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 27, 2026, 8:05 AM EDT - 8 days ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 12 days ago

US FDA declines to approve AbbVie's wrinkle treatment

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 23, 2026, 4:05 PM EDT - 12 days ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:59 PM EDT - 13 days ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 22, 2026, 12:02 PM EDT - 13 days ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 20, 2026, 2:30 AM EDT - 15 days ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

Apr 15, 2026, 8:16 AM EDT - 20 days ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

MDT

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 14, 2026, 8:50 AM EDT - 21 days ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 13, 2026, 2:24 AM EDT - 22 days ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 12, 2026, 7:15 AM EDT - 23 days ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 1:38 PM EDT - 27 days ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 8, 2026, 8:00 AM EDT - 27 days ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:53 AM EDT - 4 weeks ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 7, 2026, 9:00 AM EDT - 4 weeks ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Swiss industry body says US tariffs on pharmaceuticals will harm patients

Apr 3, 2026, 11:08 AM EDT - 4 weeks ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

AMGN AZN BMY MRK NVO

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Apr 2, 2026, 5:34 PM EDT - 4 weeks ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO AMGN BMY MRK

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

Apr 2, 2026, 5:33 PM EDT - 4 weeks ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

AMGN AZN BMY MRK NVO

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

Apr 2, 2026, 3:29 PM EDT - 4 weeks ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO AMGN BMY MRK

Global pharma companies that have publicly announced Trump drug pricing agreements

Apr 2, 2026, 2:59 PM EDT - 4 weeks ago

Global pharma companies that have publicly announced Trump drug pricing agreements

AMGN AZN BMY MRK

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:05 AM EDT - 5 weeks ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 31, 2026, 8:00 AM EDT - 5 weeks ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 27, 2026, 10:00 AM EDT - 5 weeks ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 24, 2026, 8:00 AM EDT - 6 weeks ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

Mar 20, 2026, 12:11 PM EDT - 6 weeks ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 9:26 AM EDT - 6 weeks ago

Buy Or Fear AbbVie Stock At $210?

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 19, 2026, 3:00 AM EDT - 6 weeks ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 6 weeks ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Big drugmakers must face US overcharge claims on medications for low-income patients

Mar 17, 2026, 2:32 PM EDT - 7 weeks ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 13, 2026, 9:00 AM EDT - 7 weeks ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

AbbVie Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 11:20 AM EDT - 2 months ago

AbbVie Transcript: Leerink Global Healthcare Conference 2026

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:10 AM EST - 2 months ago

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 3, 2026, 8:00 AM EST - 2 months ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Mar 2, 2026, 8:30 AM EST - 2 months ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 2 months ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

AbbVie to invest $380 million to expand US manufacturing in Illinois

Feb 23, 2026, 12:03 PM EST - 2 months ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

Feb 23, 2026, 11:00 AM EST - 2 months ago

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Feb 20, 2026, 2:00 AM EST - 2 months ago

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

AbbVie Declares Quarterly Dividend

Feb 19, 2026, 9:37 AM EST - 2 months ago

AbbVie Declares Quarterly Dividend

AbbVie Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 13, 2026, 10:00 AM EST - 2 months ago

AbbVie Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 6:49 PM EST - 2 months ago

AbbVie sues US health agency over Botox price controls

Abbvie sues US health agency over Botox

Feb 11, 2026, 5:13 PM EST - 2 months ago

Abbvie sues US health agency over Botox

55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 5 at 7:10 PM
$SLS While we Continue to See Near Miraculous survival in all pooled patients, BAT for control Arm Patients Recently Failed, 3 large Phase 3 Trials conducted by $ABBV - Miraculous Survival in this Phase 3 REGAL Trial for Second Remission Maintenance CR2 - VIALE-M Aza+VEN Phase 3 Trial FAILURE for First Remission Maintenance CR1 3 P3 Fails for BAT --- it is not complicated.
0 · Reply
SellasgpsCurativeBAT9
SellasgpsCurativeBAT9 May. 5 at 6:18 PM
$SLS 125 Million+ Cash on hand per last 10K filing. Gps will be CURATIVE in over 20+ WT1 cancer Types. GPS Ad Infinitum Dosing will generate over $50 Billion+ annually for Big Pharmaceutical Suitors. GPs has already proven effective in Mesothelioma and Platinum Resistant Ovarian Cancer settings, achieving better Phase 2 Combination trial Results with Keytruda $MRK - MOS of 18.4 months - than, Elahere $IMGN 16.4 Months, which earned FDA Approval and was bought by $ABBV for $10.1B - this is just 1 comp worth $10B. SLS009 has already shown 4 times better response in phase 2b than current SOC. Bidding war is coming $280 Per share. Don’t step over hundred dollar 💵 Bills to pick up Pennie’s. Hold with Conviction. ✌️🙏❤️‍🩹
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 5 at 5:00 PM
$ABVX $SLS From $5 and change to a High of $148 - from $270M to $14B in Market Value - all based on the Value of a Phase 3 Registrational Catalyst. - GPS Phase 3 Results Are Coming and we ARE IN THE 80th Event WINDOW - While we continue to see Miraculous all pooled survival in the REGAL Phase 3 Trial, among Control Patients on BAT and GPs Combined ... BAT / Aza+VEN Recently FAILED 3 Large Phase 3 Trials, conducted by $ABBV including Failing 2 AML Remission Maintenance Trials ... Aza+Ven is Effective at Getting Front Line patients into Remission, but its not Durable - as Dr. Yair Levy Dir. of Heme Research at Baylor Med Stated. It is not complicated - Gps is the only reason we are seeing the Extended Survival in the Regal P3. 25 Months Since the Last Patient Enrolled, we are likely to see the Final Analysis Top Line Results ANY DAY NOW. And Gps is worth every bit of $40B to Big Pharma the INSTANT we see the PR.
1 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker May. 5 at 1:23 PM
$KYTX our new CCO Mrs. Nadia Dac made her marks throughout the industry working at $LLY $JNJ $PFE $ABBV & Novartis Network is everything for scaling this baby with a proper GTM 💲💲💲
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 4 at 8:01 PM
$SLS $ABBV
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 4 at 7:53 PM
$SLS Look at the share price when the 72nd event was announced - what do you think will happen when we see the 80th? SLS Market Cap is now up over 1,000% Since the IDMC Unblinded Actual Phase 3 MOS and IR data from the INTERIM ANALYSIS at 60 Events DEC 2024. +1,000% For a Reason --- The unblinded data - Gave most HEME Industry Players $ABBV $PFE the sign Gps is Golden, now 6 months since the 72nd Event, and this far along - 25 months since enrollment completed, and median follow-up of 31 months (25-63) ALL Smart Investors must reconcile the fact the 80th event and instant share price launch could occur at any time. Now 31 months Follow-Up in a setting of "High Leukemic Risk" Dr. Kantarian Chair of MD Anderson's Leukemia Dept., REGAL Phase 3 Global Lead and Steering Committee Chair.
0 · Reply
Garibs
Garibs May. 4 at 3:29 PM
$BSX $ABBV calls on both
0 · Reply
DefenseMania
DefenseMania May. 3 at 6:45 PM
$COST $VZ $MO $ABBV https://finance.yahoo.com/markets/stocks/articles/dividend-investors-know-costco-183500369.html
0 · Reply
NRG8
NRG8 May. 3 at 12:25 PM
$JNJ $ABBV $BAC $PG $CVX .
0 · Reply
Oldpuck
Oldpuck May. 1 at 10:54 PM
$ABBV I thought ABBV had turned the corner, just like it was before earnings
1 · Reply
UsingAGodAlgorithm
UsingAGodAlgorithm May. 1 at 10:08 PM
$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile We also covered these names. $ABBV $PLTR $MU $MA
0 · Reply
SlightlyHippy
SlightlyHippy May. 1 at 9:31 PM
$JNJ & $ABBV pick up the dips!!
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 1 at 6:34 PM
$ABBV @IrishFlyGirlQueenforever congratulations to you on the rest of your life! - Guess you won't be heading to the SLS Careers Link, not that SLS is HIRING ANY ONE -- NO OPEN VACANCIES ... - Managerial MALPRACTICE to NOT BE HIRING with 2 Commercially Viable Assets. no hiring is a screaming tell, the term sheets, have been back and forth a few times. - Wishing you all your dreams come true. "Forever is our today ... who wants to Live FOREVER" 47th Like of this post --- $MRK - $ABBV
0 · Reply
Chartist0_0
Chartist0_0 May. 1 at 1:35 PM
$ABBV bought that dip. Looking for 237$ this summer.
0 · Reply
NRG8
NRG8 May. 1 at 10:43 AM
$JNJ $ABBV $BAC $PG $CVX ..
0 · Reply
AirForce1000
AirForce1000 May. 1 at 8:49 AM
$ABBV https://www.knicksnewyork.com LFG
0 · Reply
Maxwell_Osgood
Maxwell_Osgood May. 1 at 12:33 AM
$ABBV
0 · Reply
VeltrixCapitalOfficial
VeltrixCapitalOfficial Apr. 30 at 11:39 PM
I AM THE BEST TRADER ON THIS SPACE🏆 $FDX 1,750%✅ $ABBV 1560% ✅ $AMZN 1,520% ✅ $AAPL 1,300%✅ $IBM 1,250%✅ $AAPL 1,200% ✅ OTHER TRADES POSTED ON TELEGRAM LINK IN BIO
2 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 30 at 10:11 PM
$SLS $ABBV $BMY $RRHBY Own Aza VEN - they Know PRECISELY how these drugs perform in AML Remission. - They've conducted many trials, including the VIALE-M and T P3's that Recently Failed. - if AzaVEN achieved the Durable OS we are seeing Now in the REGLA trial, VIALE-M Would NOT have been Terminated. MOST IMPORTANTLY - SLS Market Value Would NOT Have Increased 1,000% Since the IDMC Unblinded Actual MOS and IR Interim Data from the Ongoing P3 - They Know Precisely that its GPS
1 · Reply
Donib11
Donib11 Apr. 30 at 8:02 PM
$ABBV not as strong of a close as I wanted, but still a nice Green Day! Let’s see 215+ tmrw 🥂
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 30 at 7:57 PM
$SLS +/- 60 Events for the Control Arm While we Await 80 Gps Phase 3 MOS is > 30 Months and Not Yet Reached. For the Short BUS Crew Aza+VEN, BAT / Best Available Treatment for REGAL P3 CONTROL ARM patients Recently FAILED 3 Large Phase 3 Trials - since August 2025, 3 P3 AZA VEN Trials Conducted by $ABBV Failed. - its Gps Immunotherapy doing what its always done, BAT - Failed... - VERONA Failed to show OS benefit - VIALE-T FAILED for aml transplant maintenance - VIALE-M FAILED for AML CR1 Remission Maintenance FAILED - 7 DIFFERENT DOSING COHORTS - all Oral, all combo's FAILED. BAT FAILED - its Gps causing the Near Miraculous survival.
0 · Reply